Expediting drug development for serious illness: Trade-offs between patient access and certainty-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expediting drug development for serious illness: Trade-offs between patient access and certainty

Published:2018-06 Issue:3 Volume:15 Page:230-234
ISSN:1740-7745
Container-title:Clinical Trials
language:en
Short-container-title:Clinical Trials

Author:

Woodcock Janet¹

Affiliation:

1. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Springs, MD 20993, USA

Publisher

SAGE Publications

Subject

Pharmacology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1740774518770656

Reference2 articles.

1. The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation

2. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway;Journal of Pharmaceutical Policy and Practice;2024-06-04

2. A framework for assessing the impact of accelerated approval;PLOS ONE;2022-06-24

3. A Framework for Assessing the Impact of Accelerated Approval;2022-02-15

4. Pathways to Treatment Development;Encyclopedia of Behavioral Neuroscience, 2nd edition;2022

5. Caregivers' Willingness to Accept Expedited Vaccine Research During the COVID-19 Pandemic: A Cross-sectional Survey;Clinical Therapeutics;2020-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP